血液性恶性瘤中的抗凝剂:数据是什么?
Ruah Alyamany1, Damon E Houghton1,2
1Section of Classical Hematology, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Hematology. American Society of Hematology. Education Program
|December 5, 2025
概括
患有血液性恶性瘤的患者面临静脉血栓栓塞 (VTE) 的高风险. 本综述涉及这些患者抗凝血治疗的挑战和策略,不包括骨髓增殖性瘤.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 血管医学 血管医学
背景情况:
- 血液性恶性瘤显著增加静脉血栓塞栓症 (VTE) 风险,特别是侵袭性淋巴瘤和多发性骨髓瘤.
- 目前的静脉瘤风险评分显示,血液恶性瘤患者的表现有限.
- 血小板缺血和凝血病对静脉瘤的预防和治疗提出了独特的挑战.
研究的目的:
- 审查目前关于血液瘤患者抗凝血策略的证据.
- 概述在这一群体中管理VTE的主要临床挑战.
- 提出指导抗凝血决策的实际策略.
主要方法:
- 在血液性恶性瘤 (不包括骨髓增殖性瘤) 中对抗凝血的系统文献综述.
- 关于VTE风险,预防和治疗的综合证据.
- 分析临床挑战和建议的管理策略.
主要成果:
- 由于出血风险和疾病特异性因素,抗凝血是复杂的.
- 现有 VTE 风险分层工具的低于最佳性能被注意到.
- 强调了针对抗凝固的量身定制方法的必要性.
结论:
- 在血液性恶性瘤中有效的抗凝血需要仔细考虑个体患者的因素.
- 需要进一步的研究来优化VTE预防和管理策略.
- 建议提供实用指南,以帮助这一高风险组的临床决策.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis III: Interprofessional Care
265
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
265
Venous Thrombosis IV: Nursing Management
185
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
185
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K


